- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03576287
Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis
Study Overview
Detailed Description
Prurigo nodularis(PN) is a chronic skin disease, characterized by severe pruritus, multiple hyperkeratotic nodules and papules often located on the extensor part of the upper and lower extremities with a symmetrical distribution. The disease often appears between 20-60 years of age affecting men and women equally.
The pathogenesis of PN is poorly understood and it is unknown whether PN is a primary dermatological disease or if it arises secondary to intense pruritus and scratching of the skin with other diseases being the cause of the itching.
A number of studies have investigated if certain biochemical parameters are involved in mediating PN e.g. studies have indicated that the small nerve fibres in dermis in lesioned skin have an increased density of Substance P (neuropeptide and a well-known mediator of pruritus. when compared to non-lesioned skin.Other studies have suggested that patients with PN have a high presence of nerve growth factor (NGF) in dermis leading to modulation of the small nerve fibres, as well as an increased number of eosinophilic granulocytes, mast- and Merkel cells. Additionally, studies have found increased levels of IL-6 and IL-31 in blood in patient with PN. However the pathogenesis of PN remains unknown.
Among patients with atopic dermatitis there is a higher frequency of patients with PN as well as PN seem to be associated with certain liver- and kidney diseases. Anxiety and depression are also more common in patients with PN.
Patients with PN suffer from impaired quality of life due to ongoing pruritus and skin lesions(5). PN is mainly treated with topical steroids, UVB, PUVA or thalidomide, although none of these treatments seem to be able to control the disease and furthermore a number of these treatments are associated with several side effects.
As the phosphodiesterase 4 (PDE4)-inhibitor (apremilast) have shown a , it is speculated that apremilast may have an effect in patients with PN. Lack of effective treatments for PN supports further development for treatment options.
This study will evaluate the anti-pruritic effect of apremilast in patients with known PN. This interventional study, will be performed at the Department of Dermatology and Allergy at Herlev and Gentofte Hospital (Gentofte site), University of Copenhagen, Hellerup, Denmark.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Hellerup, Denmark, 2900
- Recruiting
- Department of Dermato-Allergology
-
Contact:
- Tanja Todberg, MD
- Phone Number: 0045 38673207
- Email: tanja.todberg@regionh.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- > 18 years of age
- PN verified diagnosis by characteristic clinical features
- Moderate to severe PN
- Failure of local steroid and light treatment to control disease and symptoms.
- Be able to speak and understand Danish.
- Patients must have given their informed consent to the protocol and to the clinical procedures.
Exclusion Criteria:
- Patients who have received any local anti-inflammatory treatment 2 weeks prior to day 0
- Patients who have received any systemic anti-inflammatory treatment 4 weeks prior to day 0 or 5 pharmacokinetic half-lives, whichever is longer
- Patients who have received any other study medication 4 weeks prior to day 0
- Patients with other clinically significant disorders
- Patients with active TB/serious infections
- Any psychiatric condition which in the Investigators opinion would preclude the patient from adhering to the protocol or completing the study per protocol. Patients with previous endogene depression.
- Pregnancy
- Nursing
Women of child-bearing potential must use effective contraception which includes IUD, oral, injected or implanted hormonal device, hormone patch, vaginal hormonal ring og sterilization.
- Occlusive cap or condom with spermicidal cream is not considered as an effective contraception. Post-menopausal women (> 12 months of amenorrhea) are allowed not to use contraception.
- Patients who have received any live vaccines 6 weeks prior to day 0 or who are planning to receive a live vaccine during the study
- Allergy to apremilast or any of the other ingredients in Otezla®
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: apremilast
apremilast standard doses
|
Apremilast
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Reduction in mean absolute VAS-pruritus score after 12 weeks treatment with apremilast compared to mean VAS-pruritus score before treatment with apremilast
Time Frame: 12 weeks
|
1. Reduction in mean absolute VAS-pruritus score after 12 weeks treatment with apremilast compared to mean VAS-pruritus score before treatment with apremilast
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Dermatitis
- Skin Diseases, Eczematous
- Prurigo
- Neurodermatitis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 4 Inhibitors
- Apremilast
Other Study ID Numbers
- 2016-003018-29
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prurigo Nodularis
-
Trevi TherapeuticsCompletedPrurigo Nodularis | Prurigo | Nodularis PrurigoGermany
-
University Hospital MuensterNovartis PharmaceuticalsCompleted
-
Trevi TherapeuticsCompletedPruritus | Prurigo Nodularis | Prurigo | Nodularis PrurigoUnited States, Germany, Poland
-
SanofiRegeneron PharmaceuticalsNot yet recruiting
-
SanofiRegeneron PharmaceuticalsRecruitingPrurigo NodularisUnited States
-
Galderma R&DCompletedPrurigo NodularisUnited States, Austria, France, Germany, Poland, Korea, Republic of, Switzerland
-
University Hospitals Cleveland Medical CenterCelgene CorporationCompleted
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
-
Galderma R&DCompleted
-
Incyte CorporationRecruitingPrurigo NodularisUnited States
Clinical Trials on Apremilast Oral Product
-
Instituto do Cancer do Estado de São PauloRecruitingHepatocellular Carcinoma | Liver CancerBrazil
-
UAS Labs LLCCompleted
-
University Hospital, BordeauxCompleted
-
St George's, University of LondonRecruitingChronic Kidney Diseases | Heart Failure With Reduced Ejection Fraction | Hyperkalemia | ACE Inhibitor Induced Hyperkalaemia | Mineralocorticoid Resistant HyperkalemiaUnited Kingdom
-
Xenon Pharmaceuticals Inc.CompletedHealthy VolunteersUnited Kingdom
-
Duke UniversityVifor PharmaCompletedEnd Stage Renal Disease | HyperkalemiaUnited States
-
Brigham and Women's HospitalUnknownChronic Kidney Diseases | HyperkalemiaUnited States
-
Peking Union Medical College HospitalUnknown
-
National Cheng Kung UniversityNational Cheng-Kung University Hospital; Ministry of Science and Technology...Recruiting
-
Institut de Recherche pour le DeveloppementCompleted